OBJECTIVE Benign acute childhood myositis (BACM) is a self-limiting condition often following viral upper respiratory infections, manifesting with leg pain, difficulty walking, and muscle tenderness. Although the symptoms are distressing, BACM typically resolves without specific treatment, and the prognosis is generally good. This study evaluates the clinical presentation and laboratory findings of 14 pediatric BACM cases to better understand their features and facilitate differentiation from serious neurological conditions like Guillain-Barr syndrome. Material and Methods This retrospective study included 14 pediatric patients diagnosed with BACM at Ordu University between February and May 2023. Patients were selected based on their presentation with leg pain and/or difficulty walking after a viral upper respiratory infection. Demographic data, clinical symptoms, laboratory results, and the course of the disease were analyzed. RESULTS The mean age of the 14 patients was 8.923.04 years, and 85.7% were male. Neurological examinations were normal in all cases. Symptoms included leg pain (57%), fever (35%), sore throat (28.5%), and cough (35.7%). The mean creatine kinase (CK) level was 38161909 IU/L, and it decreased over 4.53.9 days. Leukopenia was observed in 35.7% of patients. Most patients showed improvement within 48 hours, and recovery took an average of 2.463.4 days. CONCLUSION BACM is commonly seen in children following viral upper respiratory infections, with the most frequent symptoms being leg pain, muscle tenderness, and difficulty walking. In our study, 85.7% of the patients were male, which aligns with prior reports indicating a higher prevalence in boys. Elevated CK levels were a hallmark of the condition, with levels returning to normal within days. The absence of neurological abnormalities in all patients and the presence of typical viral symptoms support the diagnosis of BACM. The neutrophil-to-lymphocyte ratio was consistent with a viral etiology, further supporting the viral origin of the condition.